TPST

Healthcare Biotechnology

Tempest Therapeutics, Inc.

$0.79

-0.00 -0.13% today

Price History

Not enough data

Key Stats

Market Cap

13.31M

Avg Volume

2.55M

EPS

-$3.93

52W High

$12.23

52W Low

$0.74

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-0.65

P/B Ratio

13.82

EV/EBITDA

-0.91

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(931.1%)

Return on Assets

(79.4%)

Liquidity & Leverage

Current Ratio

0.38

Quick Ratio

0.17

Total Cash

779,000

Total Debt

7.56M

About

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.